How DSOs Create Value After Dental Practice Acquisitions

Key Takeaways for Practice Owners

• Post-close EBITDA growth and multiple expansion can depend on six operational levers that DSOs execute to protect seller equity.
• Centralized revenue-cycle management, supply-chain savings, labor productivity, case acceptance, owner-dependence reduction, and multiple arbitrage each add measurable value when handled well.
• Strong DSOs move quickly, with centralized billing within 30 days, GPO enrollment within 60 days, and associate recruitment pipelines active from day one. Slower integrators often leave processes fragmented and can erode retained equity.
• Sellers can negotiate LOI language that ties earnouts to integration timelines, requests portfolio benchmarks, and requires pro-rata earnout structures to protect outcomes.
• McLerran & Associates runs a competitive bid process that surfaces vetted DSOs with proven execution on these levers. Schedule a free, confidential discovery call to see how these strategies can apply to your practice.

Lever 1: Centralized Revenue-Cycle Management and Collection-Rate Benchmarks

Revenue-cycle management (RCM) covers submitting insurance claims, following up on denials, posting payments, and collecting patient balances. Independent practices usually rely on front-desk staff for this work, which can create inconsistency. DSOs centralize these functions into a dedicated billing team, and the performance gap can be significant.

Industry reports indicate that larger dental groups often achieve higher collection rates than smaller practices. This performance gap is driven by operational differences. Data from billing platform providers shows that for DSOs with 10 or more locations, centralized billing can reduce denial rates and cut average days in accounts receivable (AR) compared with site-by-site models. These improvements in collection efficiency can translate directly into additional revenue.

Strong vs. weak contrast: A high-performing DSO deploys centralized billing before or within the first 30 days after close. A weak integrator leaves front-desk billing in place for months, which allows denial rates and AR aging to drift.

Seller action item: Request LOI language that ties any earnout (a portion of the purchase price paid after close based on performance targets) to a defined RCM integration timeline. Ask the DSO to provide current denial rates and days-in-AR benchmarks across its existing portfolio.

Lever 2: Supply-Chain Savings and Overhead Targets

Independent practices typically spend 7–8% of collections on dental supplies. Procurement analyses indicate that DSOs can pay less for supplies by centralizing purchasing, standardizing product lists, and concentrating ordering authority. Well-managed DSOs often target supply spend of 6–8% of collections, which creates meaningful savings per $1 million in production. Group purchasing organization (GPO) membership, where a DSO pools buying power across locations to negotiate lower prices, can further reduce supply costs.

Strong vs. weak contrast: A capable DSO enrolls acquired practices in its GPO within 60 days and provides location-level supply spend reporting. A weak integrator allows each location to continue ordering independently, which forfeits the volume pricing that supports its projected overhead savings.

Seller action item: Ask the DSO to document its current average supply spend as a percentage of collections across its portfolio. Request that the LOI include a representation of the GPO contracts and vendor agreements your practice will join after close.

Lever 3: Labor Productivity and Provider Utilization

Labor is usually the largest expense in a dental practice. DSOs create value by recruiting associate dentists and hygienists to expand chair utilization, standardizing scheduling protocols, and using same-store production analytics to spot underperforming locations early.

Industry analyses of same-store year-over-year comparisons across multiple DSOs representing billions in gross production have shown a wide spread between top-performing and declining practices. This spread is driven largely by operational consistency and new patient acquisition. One key driver of this consistency is labor reallocation. Centralized billing under high-performing DSOs can reduce billing full-time equivalents (FTE) per location, which frees labor budget for clinical roles that directly support production growth.

Strong vs. weak contrast: A strong DSO provides a provider recruitment pipeline and a defined scheduling optimization protocol from day one. A weak DSO acquires the practice without a staffing plan and leaves the selling doctor as the sole production driver, which compresses the value of any retained equity.

Seller action item: Before signing a letter of intent (LOI), ask the DSO to share its average same-store production growth rate across locations it has owned for more than 24 months. Confirm that the employment agreement includes associate recruitment commitments.

Lever 4: Case Acceptance and Hygiene Recall Growth

Case acceptance, the percentage of recommended treatment that patients schedule, can be one of the highest-impact production variables in a dental practice. Industry reports indicate that top-performing practices can reach 75% case acceptance compared to an industry average near 45%. This gap is often driven by clinical consistency rather than practice size. Hygiene recall, the percentage of active patients who return for scheduled reappointments, can be equally important for valuation.

DSOs often deploy standardized case presentation workflows, treatment coordinator training, imaging protocols, and automated recall campaigns to move both metrics toward institutional benchmarks. DSOs using centralized clinical dashboards have reported improvements in case acceptance rates and additional care opportunities per month per practice.

Strong vs. weak contrast: A high-performing DSO installs its case presentation system and recall automation within the first 90 days. A weak integrator leaves clinical workflows unchanged, which allows case acceptance and recall rates to stagnate and limits the EBITDA growth that supports the seller’s retained equity.

Seller action item: Request the DSO’s current portfolio-wide case acceptance and hygiene recall benchmarks. Ask how those metrics are tracked and reported at the location level after acquisition.

Lever 5: Reducing Owner Dependence to Build Transferable EBITDA

Transferable EBITDA is the portion of a practice’s earnings that can continue under new ownership without relying on the selling doctor’s personal relationships, clinical production, or administrative involvement. Buyers apply valuation multiples to this earnings base. It can be one of the main factors in both the initial acquisition price and the value of any equity the seller retains for a future recapitalization, which is a later sale of the DSO platform to a new investor.

Practices where the owner produces a high percentage of revenue typically receive lower multiples or more earnout and escrow structure than practices where the owner produces a lower percentage. Associate-led production can be a key de-risking factor that supports potential multiple expansion. Dental groups with high dependence on a single dentist can receive an EBITDA discount due to provider dependency risk.

Strong vs. weak contrast: A capable DSO has a documented associate recruitment and retention program and a management infrastructure that operates independently of the selling doctor. A weak DSO has no associate pipeline and leaves the seller’s earnout and equity value tied almost entirely to their own continued production.

Seller action item: Negotiate LOI language that requires the DSO to hire or retain a qualified associate within a defined period after close. Ensure the earnout structure is pro-rata, meaning a near-miss on an EBITDA target still pays a proportional earnout rather than an all-or-nothing outcome.

Schedule a free, confidential discovery call with McLerran & Associates to see how a competitive bid process can surface DSOs with documented associate pipelines and transferable EBITDA track records.

Lever 6: Multiple-Arbitrage Mechanics and Retained Equity

Multiple arbitrage is the difference between the multiple a DSO pays to acquire an individual practice and the higher multiple at which the DSO platform itself is valued when it later sells to a new investor. This gap can be the engine of equity value creation for sellers who keep a stake in the DSO.

Directional ranges suggest smaller owner-dependent practices trading at roughly 3.0x–5.0x EBITDA, established single-location or small multi-provider practices at 5.0x–6.5x, multi-location groups at 6.5x–8.5x, and scaled specialty or platform candidates at 8.5x–11.0x+. Platform-tier DSO targets with $10 million or more in adjusted EBITDA traded primarily in the 9–12x band during 2024 through Q2 2026, with only the very top of the market reaching up to 15x. A practice acquired at a lower multiple whose earnings are consolidated into a platform that exits at a higher multiple can generate a return on the retained equity even before EBITDA grows.

Strong vs. weak contrast: A well-capitalized DSO backed by an experienced private equity sponsor can have a credible path to a platform-level exit at a materially higher multiple. An undercapitalized DSO with fragmented operations, inconsistent reporting, or compliance gaps may never achieve a platform-quality valuation, which puts the seller’s retained equity at risk.

Seller action item: Before accepting equity as part of a deal, ask the DSO to share its current platform EBITDA, its sponsor’s prior dental exits, and the projected timeline to the next recapitalization. Equity held at the joint-venture level, which usually includes distributions, behaves differently from holding-company equity, which usually has no distributions but a higher potential ceiling. Clarify which type you are receiving.

Red-Flag Checklist: Signs a DSO Is Failing on the Six Levers

Recognizing when a DSO is not executing these levers can be as important as understanding the levers themselves. The following observable post-close failures can be some of the clearest signals that a DSO is destroying rather than creating value:

• Billing workflows left unchanged for more than 90 days after close, with no centralized RCM team assigned to the practice
• Denial rates remaining above 10% or days in AR remaining above 45 after the first full quarter under DSO ownership
• No GPO enrollment or supply standardization within 60 days, with location-level ordering continuing independently
• Absence of a same-store production reporting cadence, which leaves performance problems undetected until quarterly reviews
• No associate recruitment plan, leaving the selling doctor as the primary or sole clinical producer throughout the earnout period
• Inconsistent financial reporting across the platform, making it difficult for investors to underwrite a future recapitalization
• Staff attrition in the first 90 days driven by communication gaps, scheduling changes, or unclear reporting structures
• Aggressive immediate rebranding that alienates patients loyal to the founding doctor, which reduces recall rates and new patient flow
• Open compliance citations or unresolved payer audits that can affect a DSO valuation at the next exit
• Fragmented practice management systems across the portfolio with no integration roadmap, which prevents the centralized analytics that support EBITDA growth

Strong vs. Weak DSO Comparison Table

Lever	Strong DSO Outcome	Weak DSO Outcome	Seller Protection Language
Revenue-Cycle Management	Lower denial rates and days in AR through centralized billing	Higher denial rates and days in AR with site-by-site models	Require RCM integration timeline in LOI, and tie earnout start date to centralized billing go-live
Supply-Chain Savings	Supply spend near 6–8% of collections via GPO enrollment	Supply spend near 7–8% of collections with fragmented ordering	Request GPO enrollment documentation and current portfolio-wide supply spend percentage
Labor Productivity	Positive same-store production growth at top performers	Declining same-store production at underperformers	Request 24-month same-store production data across existing portfolio locations
Case Acceptance & Recall	High case acceptance and strong hygiene recall supporting valuation	Industry average case acceptance and recall not consistently tracked	Ask for portfolio-wide case acceptance and recall benchmarks tracked at location level
Owner Dependence Reduction	Lower owner production percentage with a documented associate pipeline	High owner production percentage and no associate recruitment plan	Negotiate pro-rata earnout provisions and require an associate hire commitment with a defined timeline
Multiple Arbitrage	Platform-tier exits at 9–12x EBITDA, with the strongest reaching 15x under experienced private equity sponsors	Fragmented platform unable to achieve institutional-quality valuation	Request sponsor’s prior dental exits, current platform EBITDA, and recapitalization timeline

Questions to Ask DSOs About Post-Close Value Creation

These questions map directly to the six levers and can be used during DSO presentations, headquarters visits, or LOI negotiations:

1. What are your current portfolio-wide denial rates and average days in AR, and what is your RCM integration timeline for newly acquired practices? (Lever 1, tests whether centralized billing is operational or still in development)
2. What GPO contracts will my practice join, and what is your current average supply spend as a percentage of collections across your portfolio? (Lever 2, verifies that procurement savings are real and transferable)
3. What is your same-store production growth rate for practices you have owned for more than 24 months, and how do you track and intervene on underperforming locations? (Lever 3, distinguishes data-driven operators from reactive ones)
4. What are your portfolio-wide case acceptance and hygiene recall benchmarks, and how are they measured at the individual location level? (Lever 4, confirms that clinical consistency infrastructure exists)
5. What is your associate recruitment process, and what commitment will you make in the LOI to hire or retain an associate within a defined period after close? (Lever 5, protects earnout and equity value from owner-dependence risk)
6. Who is your private equity sponsor, what dental platform exits have they completed, and what is the projected timeline to your next recapitalization? (Lever 6, helps you evaluate the equity component of the deal as an investment)

Conclusion: Turning Six Levers into Real-World Outcomes

Post-acquisition EBITDA growth and multiple expansion do not happen automatically after affiliating with a DSO. They usually come from disciplined operational execution across six specific levers. Industry analyses suggest that the platforms that outperform are those that execute integration carefully and plan for liquidity from the outset. Sellers who benefit most tend to enter negotiations with a clear understanding of these levers and an advisor who creates competition among buyers capable of delivering on them.

McLerran & Associates’ competitive bid process, which vets buyers, generates multiple qualified offers, and structures protective LOI language, can give sellers the leverage to request proof of delivery on every lever in this guide. The firm’s track record indicates that this approach can consistently produce stronger outcomes for sellers.

Knowing these six levers is the starting point. Verifying which DSOs actually execute them, and structuring LOI and earnout language that protects seller outcomes when they do not, can be where professional sell-side representation has the greatest impact on what an owner ultimately receives.

Schedule a free, confidential discovery call with McLerran & Associates to discuss your practice, your goals, and which DSO partners in today’s market can demonstrate a credible track record on every lever in this guide.

Frequently Asked Questions

How long does it typically take for a DSO to implement post-acquisition value-creation levers, and does the timing affect my earnout?

Integration timelines can vary significantly between high-performing and underperforming DSOs, and the difference can affect your earnout directly. Centralized billing can be deployed in roughly 14–30 days by a well-prepared DSO. A disorganized integrator may leave front-desk billing in place for 6 months or more, during which denial rates and AR aging can drift in ways that suppress the EBITDA used to measure your earnout. Supply-chain enrollment in a GPO typically takes 30–60 days. Clinical workflow standardization for case acceptance and recall generally requires about 90 days to show measurable results. When negotiating your LOI, consider requesting that earnout measurement periods begin only after defined integration milestones are met, such as centralized billing going live and a new associate starting. McLerran & Associates structures LOI and earnout language with these protections in mind, and a discovery call can be a practical way to discuss how to apply them to your situation.

What is the difference between joint-venture equity and holding-company equity in a DSO deal, and which is better for me?

In many DSO transactions, a portion of the purchase price, often 15–30%, is paid in equity rather than cash. That equity can sit at two different levels of the DSO’s corporate structure, and the distinction can be significant. Joint-venture (JV) equity is held at the level of your individual practice or a regional cluster of practices. It typically comes with distributions, which are regular cash payments from the profits of that specific group, and this can provide a more predictable income floor. Holding-company equity is held at the top of the DSO’s corporate structure alongside the private equity sponsor. It usually carries no distributions, so you receive no cash until the DSO sells to a new investor, but the upside can be higher if the platform achieves a strong exit multiple. The more suitable choice can depend on your financial situation, your confidence in the DSO’s platform trajectory, and how much near-term liquidity you need. McLerran & Associates prepares multi-year, multi-structure financial forecasts that model both options side by side, including conservative recapitalization assumptions, so you can compare real after-tax outcomes rather than headline numbers.

How does McLerran & Associates vet DSOs to protect sellers from undercapitalized or poorly run buyers?

McLerran’s vetting process treats DSO buyers similarly to how a sophisticated investor might review any investment. The firm evaluates whether the DSO’s overall platform is profitable, whether same-store revenue at practices it already owns is growing or declining, whether the management team has a track record of successful integrations, and whether the private equity sponsor backing the DSO has completed prior dental exits at strong returns. DSOs known for creating poor post-close environments, including buyers that emerged during the capital-flush period after COVID and have since struggled operationally, are blacklisted from McLerran’s process. These buyers do not reach the table. As a result, when a seller receives offers through a McLerran-run process, every bidder in the pool has already been screened for financial strength, operational capability, and seller satisfaction. That pre-vetting can be one of the most important protections a sell-side advisor provides, because as much as 40% of a DSO deal can be paid in equity, which makes the quality of the buyer as important as the headline price.

Can I negotiate earnout terms to protect myself if the DSO’s integration underperforms?

Earnout terms are often negotiable, and shaping them carefully can be one of the most important steps in protecting your total economic outcome. A common risk in a poorly structured earnout is an all-or-nothing threshold, where missing an EBITDA target by a small margin results in losing the entire earnout payment. McLerran & Associates negotiates for pro-rata earnout provisions, which means that if you come close to a target, you receive a proportional payment rather than nothing. Other protective structures can include a later earnout start date that accounts for integration disruption in the first few months, earnout periods that exclude revenue lost due to DSO-controlled decisions such as staffing changes or billing transitions, and caps on the DSO’s ability to alter fee schedules or payer contracts during the measurement period. These terms are more achievable when your advisor knows to request them and has the leverage of a competitive process. That leverage, created by having multiple qualified buyers at the table at the same time, sits at the core of McLerran’s process.

Is now a good time to sell to a DSO, given the changes in the market since 2022?

The DSO acquisition market has matured since the peak consolidation cycle of 2020–2022, and that shift can affect sellers in several ways. Platform-level multiples have compressed modestly from their peak, and DSOs are applying greater scrutiny to financials, provider continuity, and operational quality before closing. At the same time, demand for premier, Class A practices, which typically have strong EBITDA, low owner dependence, a clean payer mix, and documented hygiene recall, remains robust. Valuations for that tier of practice continue to sit near historically high levels. Practices most at risk of receiving compressed offers or losing deals in diligence tend to have heavy owner dependence, inconsistent collections, or undocumented add-backs. For owners of well-run practices generating $1.5 million or more in revenue, the current environment can reward preparation and a competitive process more than ever. McLerran & Associates can provide a candid assessment of where your practice stands in today’s market. If the timing does not appear favorable, the firm can update your valuation at no charge a year later rather than encourage a deal that does not align with your goals.